Rare disease focus Pharming specializes in rare diseases and unmet medical needs, presenting opportunities to partner on orphan drugs, specialized manufacturing, or collaborating for enzyme replacement therapy programs.

Global ops access With operations in the Netherlands, France, and the USA, Pharming offers regional manufacturing, supply chain, and regulatory capabilities to support multinational distribution and market entry strategies.

Novel production The company’s GMP-compliant platform for pure recombinant human proteins could enable cost-efficient production and potential tech licensing or co-development deals to expand manufacturing capacity.

Partnered growth Recent partnerships and distributor arrangements (e.g., OrphanPacific for Joenja in Japan) indicate a proactive channel strategy and potential for additional licensing or co-promotion collaborations in key territories.

Financial trajectory Revenue in the mid-range of $50–100M with ongoing growth in Joenja despite a legacy RUCONEST decline suggests opportunities to discuss ancillary products, pipeline milestones, and value-building collaborations with investors seeking scalable specialty biotech opportunities.